LadRx Corp (LADXD)

[strongbio]

The standard for difficult to treat cancers such as refractory pancreatic cancer or sclc is to abandon the study at 4 to 6 months based upon the first 30% of the study patients if the results are not hopeful. Its done to reduce cash burn. So some cro manager and chawla or the principal investigator knew aldoxorubicin was working before the study was fully enrolled. I called the sclc study success 13 months ago writing a log of events and known info on seeking alpha. That being said David haen did not always provide consistent or accurate info.